Truman Medical Centers earns HIMSS Enterprise Davis Award

The Truman Medical Centers (TMC) of Kansas City, Mo., has received the 2014 HIMSS Enterprise Davis Award.

Since 1994, HIMSS’s Nicholas E. Davies Award of Excellence has recognized outstanding achievement of organizations who have utilized health IT to substantially improve patient outcomes while achieving return on investment.

Davies Enterprise Award recipients include HIMSS EMR Adoption Model Stage 7 and 6 hospitals and healthcare delivery organizations. TMC is a not-for-profit health system that includes two academic acute care facilities with 600 total beds, more than 50 outpatient clinics, a behavioral health program, the Jackson County health department and a long-term care facility.

TMC serves many low-income, high-risk patients, and provides 11 percent of all uncompensated care within Missouri, at a cost of $130 million. Nevertheless, TMC has sustained excellent care coordination while maintaining a high level of care delivery that scores well above national benchmarks, according to HIMSS.

Specifically, TMC’s best practice adherence and analytical review of clinical decision support best practice protocols helped reduce the number of episodes of venous thromboembolism and hospital-acquired pressure ulcers. These clinical improvements led to nearly $8 million in savings since implementation.

TMC “has developed a culture focused on quality improvement, where the EHR is a tool that enables the staff to take action that ultimately results in improved outcomes for the underserved patients of Missouri,” said Janis Curtis, chair of the HIMSS Davies Enterprise Award Committee and business relationship management executive at Duke University Health System, in a statement.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.